Literature DB >> 8914761

Lipopolysaccharide-specific antibodies in plasma and stools of children with Shigella-associated leukemoid reaction and hemolytic-uremic syndrome.

T Azim1, F Qadri, S Ahmed, M S Sarker, R C Halder, J Hamadani, A Chowdhury, M A Wahed, M A Salam, M J Albert.   

Abstract

Antibody responses to the lipopolysaccharide (LPS) of shigellae were compared between children with uncomplicated and complicated Shigella dysenteriae 1 infection. One hundred fifteen children between 12 and 60 months of age with S. dysenteriae 1 infection were studied. Of these children, 42 had complications (leukemoid reaction and/or hemolytic-uremic syndrome [complicated shigellosis] and 73 had no complications (uncomplicated shigellosis). Antibodies to the LPS of S. dysenteriae 1 and Shigella flexneri Y were measured in plasma and stools, as were total immunoglobulin A (IgA) and IgG concentrations in plasma and the total IgA concentration in stool, on enrollment and 3 to 5 days later. In the plasma, the concentrations of homologous (IgG) and heterologous (IgA) LPS antibodies on enrollment were higher in children with complicated shigellosis than in those with uncomplicated shigellosis. In stool, the concentrations on enrollment were similar between the two groups of children. There was a rise in antibody concentrations in the plasma (homologous and heterologous) and stool (homologous) between the day of enrollment and 3 to 5 days later in children with uncomplicated shigellosis but not in those with complicated shigellosis. These findings suggest that systemic stimulation is more marked in children with complications, so that a subsequent rise in plasma antibody concentrations does not occur in these children. In contrast, the lack of a rise in stool antibody concentrations in children with complicated shigellosis is suggestive of a lower-level mucosal response. Because the duration of diarrhea before enrollment influenced the homologous antibody concentrations, children were further divided into three subgroups (short [3 to 5 days], medium [6 to 9 days], and long [> 9 days] diarrhea durations before enrollment). Comparisons of homologous antibody concentrations between the two groups of children following such subdivisions showed that in children with complicated shigellosis, antibody concentrations were higher in the plasma of children in the short diarrhea duration subgroup but lower in the stool children in the medium diarrhea duration subgroup. No differences in antibody concentrations were observed in children in the other diarrhea duration subgroups. Thus, complications in shigellosis are associated with an early and strong systemic stimulation without a concomitant stimulation of the mucosal antibody response.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8914761      PMCID: PMC170433          DOI: 10.1128/cdli.3.6.701-705.1996

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  20 in total

1.  Serologic response of patients with shiga dysentery.

Authors:  A Cáceres; L J Mata
Journal:  J Infect Dis       Date:  1974-04       Impact factor: 5.226

2.  Shiga bacillus dysentery associated with marked leukocytosis and erythrocyte fragmentation.

Authors:  M M Rahaman; A K JamiulAlam; M R Islam; W B Greenough
Journal:  Johns Hopkins Med J       Date:  1975-02

3.  Haemolytic-uraemic syndrome.

Authors:  R S Heyderman; M M Fitzpatrick; G R Barclay
Journal:  Lancet       Date:  1994-04-23       Impact factor: 79.321

4.  Gastrointestinal disease in the hemolytic-uremic syndrome.

Authors:  P F Whitington; A L Friedman; R W Chesney
Journal:  Gastroenterology       Date:  1979-04       Impact factor: 22.682

5.  Specific interaction of Escherichia coli O157:H7-derived Shiga-like toxin II with human renal endothelial cells.

Authors:  C B Louise; T G Obrig
Journal:  J Infect Dis       Date:  1995-11       Impact factor: 5.226

6.  Dissociation between cytokine mRNA expression and protein production in shigellosis.

Authors:  R Raqib; A Ljungdahl; A A Lindberg; B Wretlind; U Andersson; J Andersson
Journal:  Eur J Immunol       Date:  1996-05       Impact factor: 5.532

7.  The leukemoid reaction in shigellosis.

Authors:  T Butler; M R Islam; P K Bardhan
Journal:  Am J Dis Child       Date:  1984-02

8.  Safety and immunogenicity of the live oral auxotrophic Shigella flexneri SFL124 in adult Vietnamese volunteers.

Authors:  A Li; A Kärnell; P T Huan; P D Cam; N B Minh; L N Trâm; N P Quy; D D Trach; K Karlsson; G Lindberg
Journal:  Vaccine       Date:  1993       Impact factor: 3.641

9.  Cytokines in the stools of children with complicated shigellosis.

Authors:  T Azim; R C Halder; M S Sarker; S Ahmed; J Hamadani; A Chowdhury; F Qadri; M A Salam; R B Sack; M J Albert
Journal:  Clin Diagn Lab Immunol       Date:  1995-07

10.  The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli.

Authors:  M A Karmali; M Petric; C Lim; P C Fleming; G S Arbus; H Lior
Journal:  J Infect Dis       Date:  1985-05       Impact factor: 5.226

View more
  3 in total

Review 1.  Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.

Authors:  Myron M Levine; Karen L Kotloff; Eileen M Barry; Marcela F Pasetti; Marcelo B Sztein
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

2.  Leukemoid reaction in the pediatric population: etiologies, outcome, and implications.

Authors:  Assaf Hoofien; Havatzelet Yarden-Bilavski; Shai Ashkenazi; Gabriel Chodick; Gilat Livni
Journal:  Eur J Pediatr       Date:  2018-04-25       Impact factor: 3.183

3.  Mucosal Immune Profiles Associated with Diarrheal Disease Severity in Shigella- and Enteropathogenic Escherichia coli-Infected Children Enrolled in the Global Enteric Multicenter Study.

Authors:  Amanda D Buskirk; Esther Ndungo; Avital A Shimanovich; Diana Lam; William C Blackwelder; Usman N Ikumapayi; Bing Ma; Helen Powell; Martin Antonio; James P Nataro; James B Kaper; Marcela F Pasetti
Journal:  mBio       Date:  2022-08-04       Impact factor: 7.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.